Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Status:
Not yet recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
Study into the effects of daily use of metformin and low-dose naltrexone (LDN) for 4 weeks to
reduce symptoms, disease severity, and recovery time from COVID-19.